Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects With Advanced Refractory Solid Tumor Malignancies

Trial Profile

Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects With Advanced Refractory Solid Tumor Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs JTX 2011 (Primary) ; Nivolumab
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms ICONIC
  • Sponsors Jounce Therapeutics
  • Most Recent Events

    • 09 Aug 2017 Enrollment has commenced in the phase II Part D portion of this trial according to a Jounce Therapeutics media release.
    • 06 Jun 2017 Safety and PK results (n=25), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2017 According to a Jounce Therapeutics media release, the phase II part of the study evaluates JTX-2011 as a monotherapy across more than three disease-specific expansion cohorts in solid tumors, including patients with head and neck squamous cell cancer (HNSCC) and non-small cell lung cancer (NSCLC) and in combination with nivolumab and in over five cohorts, including HNSCC, NSCLC, triple negative breast cancer, melanoma and gastric cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top